Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Exelixis securities investigation...
Regulatory securities investigation

Exelixis securities investigation over guidance

Analysis based on 11 articles · First reported Aug 10, 2026 · Last updated Aug 12, 2026

Sentiment
-30
Attention
2
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Exelixis shares dropped in after-hours trading after the company reported Q2 revenue below consensus and lowered its full-year 2026 revenue guidance. The investigation adds legal and reputational risk, potentially further pressuring the stock and investor sentiment.

Biotechnology Pharmaceuticals
Event Summary

Levi & Korsinsky, a securities litigation firm, commenced an investigation into Exelixis, Inc. (Nasdaq: EXEL) concerning potential violations of federal securities laws. The investigation focuses on whether Exelixis made materially false or misleading statements regarding its full-year 2026 revenue guidance and the commercial ramp of its neuroendocrine-tumor business. On May 5, 2026, CFO Bong Go reiterated full-year 2026 financial guidance, and CEO Michael Morrissey described the company as 'off to a strong start in 2026' with CABOMETYX as a market leader. However, after reporting Q2 revenue of approximately $628.7 million, which missed consensus estimates, Exelixis lowered and narrowed its full-year 2026 revenue outlook, attributing the shortfall to a slower-than-expected ramp in its neuroendocrine-tumor business. The stock declined in after-hours trading. The investigation concerns when management first identified the slower ramp relative to the date guidance was reiterated. Levi & Korsinsky is seeking investors who suffered losses to participate in the investigation.

Key Actions
100 Exelixis lowered full-year guidance
90 Exelixis reported Q2 revenue
80 Levi & Korsinsky commenced investigation Exelixis
70 Bong Go reiterated financial guidance Exelixis
60 Michael Morrissey made positive statements Exelixis
Entities Involved
stock
Exelixis
Exelixis is the subject of the investigation. Its shares fell after reporting Q2 revenue below consensus and lowering full-year guidance, and it now faces potential securities litigation.
Importance 100.0 Sentiment -40.0
priv
Levi & Korsinsky
Levi & Korsinsky commenced the investigation into Exelixis, positioning itself to represent shareholders and potentially recover losses.
Importance 80.0 Sentiment 20.0
per
Bong Go
As CFO, Bong Go reiterated full-year 2026 guidance on May 5, 2026, which is central to the investigation into potentially misleading statements.
Importance 60.0 Sentiment -20.0
per
Michael Morrissey
As CEO, Michael Morrissey made positive statements about the company's performance and CABOMETYX, which are also under scrutiny in the investigation.
Importance 50.0 Sentiment -20.0
per
Joseph E. Levi
Joseph E. Levi is a partner at Levi & Korsinsky and a contact for investors seeking to participate in the investigation.
Importance 30.0 Sentiment 10.0
exch
Nasdaq
Nasdaq is the exchange where Exelixis is listed; the investigation and stock decline are reflected in its trading.
Importance 10.0 Sentiment 0.0
Relationships
Levi & Korsinsky related ↔ Joseph E. Levi
Levi & Korsinsky related ↔ Nasdaq
Joseph E. Levi related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.